Skip to Content
E. Jason Abel, MD, FACS

Contact Dr. Abel

E-mail:
abel@urology.wisc.edu

Phone:
(608) 263-4563

Mail:
UW Medical Foundation Centennial Building
1685 Highland Ave
Madison, WI 53705-2281

E. Jason Abel, MD, FACS

Assistant Professor
Department of Urology

Education

  • BS, Zoology; BA, Molecular Biology, University of Texas at Austin, 1998
  • MD, The University of Texas at Houston Medical School, 2003
  • Residency, University of Utah Division of Urology, Salt Lake City, UT, 2008
  • Fellowship, Urologic Oncology, University of Texas M.D. Anderson Cancer Center, Houston, TX, 2010

Dr. Abel specializes in the surgical treatment of urologic malignancies. He has advanced training to surgically manage all types of genitourinary cancers including prostate cancer, bladder cancer, kidney cancer, testis cancer and penile cancer.

Clinical Specialties

Dr. Abel is certified by the American Board of Urology. He performs open and laparoscopic surgery including surgery using the daVinci robot. Dr Abel’s philosophy is to provide maximal quality of life to patients by using minimally invasive approaches to cancer therapy whenever appropriate. He has a special interest in the treatment of localized and locally advanced kidney cancer.

Research Interests

Dr. Abel conducts clinical, translational, and basic research in urologic oncology. Clinical and translational interests include improving patient outcomes after complex urologic surgery, improving prognostic ability for patient decision making, and multidisciplinary care of kidney cancer.

Dr. Abel serves on the board of directors for the Society of Urologic Oncology (SUO) Clinical Trials Consortium.

Funding/Grants
  • Role of NFXB/HIF2A Axis in Renal Cell Carcinoma Progression
    Funding Agency: National Institutes of Health (NIH); National Cancer Institute (NCI) Career Development Award 1K08CA178168-01
    Principal Investigator(s): E. Jason Abel, MD, FACS
    More Information

Recent Publications
  • Abel EJ, Margulis V, Bauman TM, Karam JA, Christensen WP, Krabbe LM, Haddad A, Golla V, Wood CG. Risk Factors for Recurrence After Surgery in Non- metastatic RCC with Thrombus; a Contemporary Multicenter Analysis. BJU Int. 2015 Aug 25.
    [PubMed ID: 26305276]
    More Information
  • Blute ML, Abel EJ, Downs TM, Kelcz F, Jarrard DF. Addressing the need for repeat prostate biopsy: new technology and approaches. Nat Rev Urol 2015 Aug; 12(8):435-44.
    [PubMed ID: 26171803]
    More Information
  • Blute ML, Rushmer TJ, Shi F, Fuller BJ, Abel EJ, Jarrard DF, Downs TM. Renin-Angiotensin Inhibitors Decrease Recurrence after Transurethral Resection of Bladder Tumor in Nonmuscle Invasive Bladder Cancer. J. Urol. 2015 Jul 11.
    [PubMed ID: 26173101]
    More Information
  • Potretzke AM, Wong KS, Shi F, Christensen W, Downs TM, Abel EJ. Highest risk of symptomatic venous thromboembolic events after radical cystectomy occurs in patients with obesity or nonurothelial cancers. Urol Ann 2015 Jul-Sep; 7(3):355-60.
    [PubMed ID: 26229325, PMCID: 4518374]
    More Information
  • Karam JA, Devine CE, Fellman BM, Urbauer DL, Abel EJ, Allaf ME, Bex A, Lane BR, Thompson RH, Wood CG. Variability of inter-observer agreement on feasibility of partial nephrectomy before and after neoadjuvant axitinib for locally advanced renal cell carcinoma (RCC): independent analysis from a phase II trial. BJU Int. 2015 Jun 1.
    [PubMed ID: 26033220]
    More Information
  • Haddad AQ, Leibovich BC, Abel EJ, Luo JH, Krabbe LM, Thompson RH, Heckman JE, Merrill MM, Gayed BA, Sagalowsky AI, Boorjian SA, Wood CG, Margulis V. Preoperative multivariable prognostic models for prediction of survival and major complications following surgical resection of renal cell carcinoma with suprahepatic caval tumor thrombus. Urol. Oncol. 2015 Sep; 33(9):388.e1-9.
    [PubMed ID: 26004163]
    More Information
  • Abel EJ, Heckman JE, Hinshaw L, Best S, Lubner M, Jarrard DF, Downs TM, Nakada SY, Lee FT, Huang W, Ziemlewicz T. Multi-Quadrant Biopsy Technique Improves Diagnostic Ability in Large Heterogeneous Renal Masses. J. Urol. 2015 Mar 30.
    [PubMed ID: 25837535]
    More Information
  • Prince J, Bultman E, Hinshaw L, Drewry A, Blute M, Best S, Lee FT, Ziemlewicz T, Lubner M, Shi F, Nakada SY, Abel EJ. Patient and tumor characteristics can predict nondiagnostic renal mass biopsy findings. J. Urol. 2015 Jun; 193(6):1899-904.
    [PubMed ID: 25498574]
    More Information
  • Abel EJ, Linder BJ, Bauman TM, Bauer RM, Thompson RH, Thapa P, Devon ON, Tarrell RF, Frank I, Jarrard DF, Downs TM, Boorjian SA. Perioperative blood transfusion and radical cystectomy: does timing of transfusion affect bladder cancer mortality? Eur. Urol. 2014 Dec; 66(6):1139-47.
    [PubMed ID: 25194909]
    More Information
  • Moreland AJ, Ziemlewicz TJ, Best SL, Hinshaw JL, Lubner MG, Alexander ML, Brace CL, Kitchin DR, Hedican SP, Nakada SY, Lee FT, Abel EJ. High-powered microwave ablation of t1a renal cell carcinoma: safety and initial clinical evaluation. J. Endourol. 2014 Sep; 28(9):1046-52.
    [PubMed ID: 24846329]
    More Information


webmaster@surgery.wisc.edu Copyright © 2015 The Board of Regents of the University of Wisconsin System